Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Despite fluctuating safety worries, Pfizer's COX-2 inhibitors, Celebrex and Bextra, have helped quadruple the company's Q4 2004 figures, with sales increasing in the wake of Merck's Vioxx withdrawal.
Subscribe to our email newsletter
Worldwide sales of Celebrex topped $3.3 billion and Bextra sales totaled nearly $1.3 billion in 2004. Pfizer’s Lipitor also delivered strong double-digit revenue growth, becoming the world’s first $10 billion pharmaceutical product.
Pfizer revenues for the fourth quarter of 2004 grew 7% to $14.924 billion, compared to the fourth quarter of 2003, while revenues for full-year 2004 grew 17% to $52.516 billion, compared to 2003.
Fourth-quarter human health revenue growth was led by Lipitor (up 23%), Celebrex (up 24%), Bextra (up 57%), Zyvox (up 73%), Campto/Camptosar (up 129%), Detrol (up 22%), and Xalatan/Xalacom (up 23%), partially offset by sales declines for Neurontin, Diflucan, and Accupril due to generic competition and Zithromax due to weak respiratory-infection trends.
Full-year human health worldwide revenue growth of 17% was driven largely by Lipitor (up 18%), Zoloft (up 8%), Geodon (up 32%), Relpax (up 99%), Vfend (up 44%), and other key products – Celebrex, Bextra, Xalatan, Detrol, and Zyvox – partially offset by sales declines for Viagra, Diflucan, and Zithromax.